Table 1 Baseline characteristics of the patients who reached the primary end-point (day 28)
From: Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial
Quinine | Atovaquone/Proguanil | Artemether/Lumefantrine | ||
|---|---|---|---|---|
n | 30 | 30 | 30 | |
sex | m/f | 16/14 | 16/14 | 18/12 |
age | range | 6 – 50 | 6 – 35 | 8 – 40 |
mean | 19.2 | 19.9 | 18.1 | |
median | 16 | 18 | 17 | |
Temperature (C°) | range | 36.0 – 39.5 | 36.0 – 39.3 | 35.6 – 39.9 |
mean | 37.4 | 37.3 | 37.5 | |
median | 37.2 | 37.3 | 37.4 | |
Parasitaemia | range | 360 – 63,000 | 400 – 69,880 | 480 – 83,600 |
mean | 15,469 | 13,028 | 21,189 | |
median | 6,740 | 4,960 | 9,300 | |
Symptoms | Headache | 30 | 30 | 30 |
Nausea/vomiting | 21 | 17 | 22 | |
Shivering | 23 | 26 | 21 | |
Diarrhea | 4 | 2 | 3 | |
Actual daily dose (mg/kg) | range | 30.5 – 36 | 15 – 23 | 2.3 – 4.6 |
mean | 34.9 | 19.5 | 3.4 | |
stdev | 1.6 | 1.9 | 0.6 |